Stock AnalizElevance Health (ELV) earnings for the quarter ended September 2026: EPS beats estimates
Elevance Health reported results for the quarter ended September 2026 on October 21, 2026. Adjusted earnings per share came in at $6.99 against the analysts’ average forecast of $4.69, a beat of 48.9%.
Revenue for the quarter was $50.44 billion, down 0.5% from $50.71 billion in the same quarter a year earlier.
The market’s verdict: the stock fell 1.4% on the first trading day after the report.
The last four quarters
Elevance Health has beaten the analysts’ EPS forecast in 4 of the last 4 quarters.
| Quarter | EPS | Forecast | Surprise | Revenue growth | Price reaction |
|---|---|---|---|---|---|
| Sep 2026 | $6.99 | $4.69 | +48.9% | −1% | −1.4% |
| Jun 2026 | $7.45 | $6.21 | +20.0% | +1% | −12.6% |
| Mar 2026 | $12.58 | $10.81 | +16.4% | +3% | +5.5% |
| Dec 2025 | $3.33 | $3.09 | +7.6% | +9% | +7.4% |
What comes next
Analysts expect EPS of $2.07 for the next quarter on average and $29.14 for the fiscal year ending December 31, 2026.
The average analyst price target is $482.38, 12% above the current price of $429.69.
Valuation and score
Elevance Health scores 3.0 out of 5 overall on Stock Analiz (good, with some weak spots), trades at a trailing P/E of about 18.3, and its intrinsic value under moderate assumptions is about 1% above the current market value. Full Elevance Health analysis with 10 years of financials
Frequently asked questions
What was Elevance Health’s EPS for the quarter ended September 2026?
$6.99 adjusted per share, against an analyst consensus of $4.69.
How much revenue did Elevance Health report?
$50.44 billion, down 0.5% year over year.
More
This report was written automatically from the published numbers within hours of the release. It is information, not investment advice.